

Study with brain tissue from human epilepsy patients confirms that brain cells express CombiGene's candidate drug CG01

CombiGene has, in collaboration with Associate Professor David Woldbye at University of Copenhagen and Professor Merab Kokaia at Lund University, carried out a so-called "human expression study", i.e. a study using brain tissue from human epilepsy patients. A similar study with positive results has previously been carried out when neuropeptide Y was directly applied to human tissue of the same kind. Neuropeptide Y is the neurotransmitter that CG01 expresses in the brain via genes. This is, however, the first study testing the candidate drug, CG01, in human tissue.

Initial data from the study shows that the therapeutic genes encoded by CG01 are expressed in epileptic human tissue, i.e. the genes are incorporated into the cells when the candidate drug is applied. The study shows for the first time that this method of administering genes encoded by the candidate drug works in human tissue.

The human tissue used in this study is unique since it derives from epilepsy patients who are resistant to traditional medication. It is exactly this patient group that CombiGene initially aims to treat with CG01. Consequently, it is most encouraging that CG01 expresses therapeutic genes in the brain cells of tissue from these potential patients. Final data from the study is expected to be ready during the first quarter of 2018.

"The study is an important step in the development of CombiGene's drug candidate," says Associate Professor David Woldbye, one of the scientific founders of CombiGene. "This study has given us further evidence that CG01 has the potential to become an important part of treatment options for epilepsy patients for whom effective medication is currently lacking."

This information is information that CombiGene AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted, by CEO Jan Nilsson, for publication on Dec 14 2017.

About CombiGene AB

By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. The current focus is on continuing to develop this method into an effective and safe therapy for epilepsy patients, but the method may also have development potential as a means of treating other neurological disorders. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicom Village in Lund, Sweden. The company is public and listed on the Swedish marketplace AktieTorget. www.combigene.com

For further information:

CombiGene AB (publ)
Jan Nilsson, CEO
Tel: +46 (0)704 66 31 63
E-mail: jan.nilsson@combigene.com

Please read **MORE FROM THE COMPANY**, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Other issues of **MORE FROM THE COMPANY** and press releases are available at www.combigene.com

www.combigene.com

CombiGene AB (publ) Medicom Village, SE-223 81 Lund, Sweden
info@combigene.com
www.combigene.com